Grace Therapeutics, Inc.
GRCE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | 0.01 | -0.11 | -0.13 |
| FCF Yield | -6.65% | -3.81% | -9.44% | -9.56% |
| EV / EBITDA | -32.62 | -8.84 | -24.06 | -8.64 |
| Quality | ||||
| ROIC | -3.87% | -4.58% | 7.56% | -5.46% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 3.36 | 0.54 | -4.64 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -75.16% | 39.03% | 28.21% | 2.93% |
| Safety | ||||
| Net Debt / EBITDA | 17.98 | 6.48 | 58.24 | 2.99 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -27,045.00 | 0.00 |